SOL GEL TECHNOLOGIES LTD
NASDAQ: SLGL (Sol-Gel Technologies Ltd.)
Last update: 4 hours ago35.75
-0.29 (-0.80%)
| Previous Close | 36.04 |
| Open | 37.18 |
| Volume | 24,363 |
| Avg. Volume (3M) | 22,126 |
| Market Cap | 99,591,920 |
| Price / Sales | 4.20 |
| Price / Book | 3.15 |
| 52 Weeks Range | |
| Earnings Date | 20 Nov 2025 |
| Profit Margin | -107.77% |
| Operating Margin (TTM) | -879.63% |
| Diluted EPS (TTM) | -4.70 |
| Quarterly Revenue Growth (YOY) | 121.20% |
| Total Debt/Equity (MRQ) | 5.84% |
| Current Ratio (MRQ) | 5.12 |
| Operating Cash Flow (TTM) | -13.89 M |
| Levered Free Cash Flow (TTM) | -9.91 M |
| Return on Assets (TTM) | -26.82% |
| Return on Equity (TTM) | -49.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Sol-Gel Technologies Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | -0.88 |
|
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 70.00% |
| % Held by Institutions | 24.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Migdal Insurance & Financial Holdings Ltd. | 30 Sep 2025 | 122,755 |
| Allworth Financial Lp | 30 Jun 2025 | 5 |
| 52 Weeks Range | ||
| Median | 50.00 (39.86%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Oct 2025 | 50.00 (39.86%) | Buy | 39.81 |
| Date | Type | Details |
|---|---|---|
| 20 Nov 2025 | Announcement | Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates |
| 04 Sep 2025 | Announcement | Sol-Gel Announces Health Canada Approval of EPSOLAY® |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |